Karyopharm Therapeutics Inc Stock Price, News & Analysis

Karyopharm Therapeutics (Nasdaq: KPTI) announced promising results from a Phase 1 study on selinexor combined with ruxolitinib in treatment-naïve myelofibrosis patients. At Week 24, the 60mg dose achieved a 92% SVR35 and 78% TSS50 in the efficacy evaluable population, with 79% SVR35 and 58% TSS50 in the intent-to-treat population. The safety profile was generally tolerable, with common adverse effects like nausea and anemia. Karyopharm is planning to initiate a pivotal Phase 3 study in the first half of 2023 to further explore this combination therapy. Investor interest is high, with a webcast featuring key opinion leader Dr. John Mascarenhas discussing the study's implications. These results could potentially transform treatment options for myelofibrosis.

Karyopharm Therapeutics (NASDAQ: KPTI) announces the presentation of updated data from its Phase 1 study on selinexor, combined with ruxolitinib, to treat treatment-naïve myelofibrosis. These findings will be showcased at the AACR Annual Meeting 2023 in Orlando, Florida, on April 18, 2023. The study's poster session will cover 12 and 24-week data across all patients, including the recommended dose. Additionally, Karyopharm will host an investor webcast on the same day at 4:30 p.m. ET, featuring a key opinion leader discussing the therapy's potential and the unmet medical need in this patient population. Selinexor, marketed as XPOVIO, is a pioneering treatment in the field of oncology, having received regulatory approvals in various countries for multiple cancer indications.